Develops medical devices and diagnostic products for reproductive health, focusing on improving patient outcomes in fertility management.
Femasys Inc. is a prominent biomedical company specializing in the women's healthcare market within the United States. The company is dedicated to developing innovative solutions for permanent birth control, including FemBloc and FemChec, as well as offering FemaSeed, an artificial insemination solution. Femasys also provides FemCerv, a biopsy device designed for endocervical curettage, and is advancing FemEMB, a product candidate crucial for endometrial sampling in the detection of uterine cancer.
In addition to its development efforts, Femasys commercializes the FemVue saline-air device across the United States, Europe, Canada, Japan, and other international markets. The company's products cater to obstetrics-gynecological physicians, reproductive endocrinologists, and various women's healthcare provider organizations, enhancing their capabilities in infertility treatments and non-surgical product technologies.
Established in 2004 and headquartered in Suwanee, Georgia, Femasys Inc. continues to expand its footprint in women's healthcare through innovation and strategic commercialization efforts. With a strong commitment to advancing reproductive health technologies, the company strives to improve patient outcomes and enhance healthcare options for women globally.